BHC250516P3000
- 0.07
- 0.000.00%
Bausch Health Newsroom
Trump Renews Push for Most-Favored-Nation Drug Pricing. What It All Means
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
Weak Jobs Report Raises Odds of Bank of Canada Cut in June
A U.S.-U.K. Trade Deal May Not Offer Hope for Canada, Other Markets -- Market Talk
Bausch Health Companies Inc. (BHC): Among Billionaire John Paulson's Stocks With Huge Upside Potential
Bausch + Lomb Brief: Says Received European CE Mark Approval for Preloaded LuxLife Full Range of Vision Intraocular Lens
Canadian American Business Council CEO Says She Was 'Heartened' by Comments From Trump-Carney Meeting
Raymond James Maintains Bausch Health(BHC.US) With Hold Rating, Maintains Target Price $8
Canadian Export Growth to Countries Beyond U.S. Unlikely to Last -- Market Talk
Bausch Health, Salix Announce Data on Xifaxan After OHE Hospitalization
Bausch Health Up 3.5% In US Premarket As Says New Analysis Suggests Efficacy of Xifaxan
Xifaxan(R) (Rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated With Reduced Risk of 30-Day OHE Rehospitalization
Canada's Carney Seeks New Deals From Talks With Trump -- WSJ
Raymond James Maintains Bausch Health(BHC.US) With Hold Rating, Cuts Target Price to $8
Xifaxan (Rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated With Reduced Risk of 30-Day OHE Rehospitalization
Canadian Stock Movers for Monday | Parkland Corp Was the Top Gainer; Materials Led Gains
TD Cowen Maintains Bausch Health(BHC.US) With Hold Rating, Cuts Target Price to $7
Bausch Health Companies: Hold Rating Amid Lowered Earnings and Profitability Concerns
Bausch Health Is Maintained at Sector Perform by RBC Capital
Bausch Health Companies Analyst Ratings